Related Experiment Videos
The HCV and HIV coinfected patient: what have we learned about pathophysiology?
Andrew H Talal1, P Wilfredo Canchis, Ira Jacobson
1Weill Medical College of Cornell University, 525 East 68th Street, A354, New York, NY 10021, USA. aht2002@med.cornell.edu
Insights
Hepatitis C virus (HCV) infection is common in HIV patients. Optimal management of HCV in coinfected individuals requires further research due to unique challenges and treatment considerations.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) coinfection is prevalent in Human Immunodeficiency Virus (HIV)-infected individuals, affecting one-quarter to one-third of this population.
- Shared transmission routes contribute to the high co-occurrence of these single-stranded RNA viruses.
- While HIV prognosis is linked to viral load, HCV prognosis and the mechanisms of HCV-induced hepatic fibrosis remain less understood.
Purpose of the Study:
- To highlight the importance of treating HCV in coinfected patients.
- To discuss the complexities and considerations in managing HCV in the context of HIV.
- To identify areas requiring further research for optimal patient care.
Main Methods:
- Review of existing literature on HCV and HIV coinfection.
- Analysis of virologic and pathogenic aspects of both viral infections.
- Discussion of treatment challenges and outcomes in coinfected patients.
Main Results:
- HCV infection is a significant concern in HIV-positive individuals.
- The pathogenesis of HCV-induced hepatic fibrosis is complex and not fully elucidated.
- Effective management of HCV in coinfected patients is crucial due to improved survival rates for HIV.
Conclusions:
- Treatment of HCV is increasingly vital for HIV-infected patients.
- Key considerations include treatment timing, side effect management, and potential drug interactions.
- Further research is essential to establish optimal management strategies for HCV in HIV-HCV coinfected individuals.
Abstract:
Hepatitis C virus (HCV) infection is an important problem in individuals who are also infected with HIV. HCV infection is very common in HIV-infected individuals, occurring in approximately one quarter to one third of this group, presumably as a consequence of shared routes of transmission related to virologic and pathogenic aspects of the viral infections. Although both are single-stranded RNA viruses and share similar epidemiologic properties, there are many important differences. Although the quantity of HIV RNA in plasma is an important prognostic determinant of HIV infection, this has not been shown with HCV. A direct relationship is apparent between HIV-related destruction of CD4 cells and the clinical consequences of the disease resulting from immunodeficiency. The pathogenesis of HCV, which occurs as a consequence of hepatic fibrosis, is much more complex. The hepatic stellate cell, the major producer of the extracellular matrix protein, is the main contributor to hepatic fibrosis, but the mechanism by which HCV induces hepatic fibrosis remains unclear. Treatment of HCV is increasingly important in HIV-infected patients due to improved HIV-associated morbidity and mortality and due to the frequency with which HCV occurs in patients with HIV-HCV coinfection. Timing of treatment initiation, management of side effects, and possible effects of anti-HCV therapy on HIV are among the issues that need consideration. Also, because several issues concerning HCV are unique to coinfected patients, further research is needed to determine optimal management of HCV in this setting.